Maze Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MAZE | GPCR | KLRA | LXRX | ARWR | IONS | |
|---|---|---|---|---|---|---|
| Market cap | 1.54B | 1.71B | 1.47B | 734.18M | 8.58B | 7.26B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -8.6 | -11.3 | -2.6 | -8.7 | -12.3 | -39.3 |
| Price/book | 3.4 | 1.3 | 1.3 | 4.2 | 18.4 | 16.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −5.11% | −15.40% | −55.35% | +16.67% | +68.88% | −35.85% |
| Today | +2.18% | −6.38% | −2.41% | −1.79% | −3.22% | −3.56% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All MAZE news ›Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
markets.businessinsider.com Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026 Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated…
An officer proposes selling 34,501 shares held by two trusts at Maze Therapeutics (Nasdaq: MAZE).
The proposed shares are attributed to two trusts, while the notice also records their common-stock sales from July through September 2026. Sentiment and the balance of points Rhea-AI Sentiment reads the wording of the document, how…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
markets.businessinsider.com1
-
stocktitan.net1
-
tradingview.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.